Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks, with positive data from their Phase 2 prophylaxis and HAE studies, as well as continued open-label extension studies, showcasing the potential efficacy and safety of their oral bradykinin B2 receptor antagonist, deucrictibant. Their key upcoming catalyst, the RAPIDe-3 topline data, is expected in 4Q25 and has the potential to significantly increase the company's value and market share within the HAE space. With this positive outlook and potential market growth, Pharvaris presents as a strong opportunity for investors.

Pharvaris is a late-stage biopharmaceutical company with a current focus on developing deucrictibant, an oral bradykinin B2 receptor antagonist for the treatment and prevention of hereditary angioedema (HAE) attacks. While the company has shown positive data in Phase 2 studies and is planning pivotal Phase 3 trials for both on-demand and prophylactic treatment, there are several key risks that could impede the success of deucrictibant, including competition in the HAE market, potential delays in regulatory approvals, and the emergence of new therapies that could limit deucrictibant's market share. Despite the company's progress and potential, it is still subject to the same risks that apply to the biotech industry as a whole, and as such, we have a negative outlook on Pharvaris stock.